ALC News

Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value

Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory

Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger

Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon

STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon